St. Luke’s Provides Treatment for COVID ‘Long Haulers’

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

April 16, 2021

St. Luke’s has introduced its new COVID Recovery Clinic, a program dedicated to the treatment of post-COVID-19 patients with lingering symptoms.

St. Luke’s recognizes the prevalence of “long COVID” symptoms and the need to care for patients afflicted by these symptoms appropriately.  Incorporating the expertise of a half dozen different kinds of medical specialists, the program promises a coordinated, multidisciplinary approach to Post-Acute Sequelae of COVID, known as PASC.  Participants will benefit from specialized evaluation and a personalized treatment plan.

“Many people recovering from COVID continue to have long-lasting symptoms that impact their day-to-day lives. St. Luke’s is committed to helping these patients get access to the most appropriate care so they can find relief,” said St. Luke’s Senior Regional Medical Director Dennis McGorry, MD, who is spearheading the program.

Nationally, PASC of varying severity is being reported in up to 30% of adults and children following COVID infection.

Most typical COVID cases resolve in four weeks, explained Jeffrey Jahre, MD, St. Luke’s Vice President of Medical & Academic Affairs and Section Chief Emeritus of Infectious Diseases.  But for some, the symptoms aren’t going away. “Patients are going to their doctor, asking, ‘What’s wrong with me?’ In many cases, people are not getting the appropriate care.”

The most common after-effects these patients, or “long haulers,” experience include extreme fatigue, memory impairment, known as “brain fog,” anxiety and depression, breathing difficulty and heart muscle irregularities or irregular heartbeats.

Patients with persistent symptoms beyond four weeks are advised to go to their St. Luke’s primary care physician, who will be able to evaluate them and may refer them to the COVID Recovery Clinic for further treatment by appropriate medical specialists.

Depending on a patient’s specific symptoms and their severity, treatment can include cognitive and memory retraining, physical and occupational therapy, medication and group therapy for behavioral health issues as well as other interventions to address neurologic, pulmonary and cardiac problems.

St. Luke’s has taken steps to help providers manage PASC, such as building a “smart set” algorithm into the electronic medical record system. The smart set guides physicians on ordering tests and imaging scans based on patients’ symptoms.

While some COVID after-effects may be mild, McGorry said, “The key is not missing something serious like a pulmonary embolism or cardiomyopathy (heart muscle issue) in these patients.”

spot_img

DON'T MISS

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.